Media coverage about Cellectis (NASDAQ:CLLS) has been trending positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellectis earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.075306807567 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Global Hairy Cell Leukemia Therapeutics Market 2018 – AbbVie Inc, Cellectis SA, Incyte Corp (truthfuleditor.com)
- Zacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.66 Per Share (americanbankingnews.com)
- BidaskClub Lowers Cellectis (CLLS) to Buy (americanbankingnews.com)
- Cellectis (CLLS) Rating Increased to Strong-Buy at BidaskClub (americanbankingnews.com)
- Cellectis (CLLS) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
Several equities analysts recently weighed in on CLLS shares. ValuEngine cut shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of Cellectis in a research note on Thursday, December 28th. BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Finally, Nomura lifted their price objective on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research note on Wednesday, March 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Cellectis has a consensus rating of “Hold” and an average price target of $42.67.
TRADEMARK VIOLATION WARNING: This news story was first posted by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://baseballnewssource.com/2018/03/29/favorable-press-coverage-somewhat-unlikely-to-affect-cellectis-clls-stock-price/1972022.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.